Back to Search
Start Over
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.
- Source :
-
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2011 Apr; Vol. 67 (4), pp. 967-9. Date of Electronic Publication: 2011 Feb 17. - Publication Year :
- 2011
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents administration & dosage
Antineoplastic Agents pharmacokinetics
Benzamides
Chronic Disease
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Hypereosinophilic Syndrome pathology
Imatinib Mesylate
Male
Middle Aged
Oncogene Proteins, Fusion genetics
Piperazines administration & dosage
Piperazines pharmacokinetics
Pyrimidines administration & dosage
Pyrimidines pharmacokinetics
Receptor, Platelet-Derived Growth Factor alpha genetics
Remission Induction methods
Retrospective Studies
Splenomegaly etiology
Time Factors
Young Adult
mRNA Cleavage and Polyadenylation Factors genetics
Antineoplastic Agents therapeutic use
Hypereosinophilic Syndrome drug therapy
Piperazines therapeutic use
Pyrimidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0843
- Volume :
- 67
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Cancer chemotherapy and pharmacology
- Publication Type :
- Report
- Accession number :
- 21327932
- Full Text :
- https://doi.org/10.1007/s00280-011-1582-3